US-based MyOme and Ms.Medicine have formed a strategic alliance to introduce genomics in primary care for women to transform personalised primary care.
The collaboration will allow Ms.Medicine patients to access MyOme’s Proactive Health portfolio, which includes polygenic risk scores, monogenic disease screening, and pharmacogenomic insights.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With these insights, clinicians will be able to use genomic data to detect health risks at an early stage, customise prevention strategies, inform treatment decisions, and deliver personalised care for women across different stages of life.
For example, a patient with a family history of breast cancer may undergo genomic testing during her annual visit.
Using MyOme’s integrated report, providers can assess both common (polygenic) and rare (monogenic) genetic risks, decide on enhanced screening, and utilise pharmacogenomic data for preventive medication, all within standard clinical workflows.
MyOme tests are offered through an existing collaboration with the Nest Genomics clinical decision-support platform.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis platform integrates genomic insights into electronic health records (EHR) directly, allowing clinicians to order genetic testing and interpret data at the point of care.
The partnership aims to serve as a model for women’s health programmes across the country, operationalising genomics-informed care across primary care, combining disease risk assessment, pharmacogenomics, and whole-genome sequencing into a single approach for prevention and lifelong health.
MyOme CEO Premal Shah said: “Embedding MyOme’s genomic insights in Ms.Medicine’s existing workflow lets clinicians identify risk earlier and drive patients into standard-of-care interventions at the right time — when disease can be avoided, delayed, or caught early and treated with lower costs and less-intensive interventions.”
Ms.Medicine CEO Lisa Larkin said: “Our mission has always been to elevate the standard-of-care by making it individualised, evidence-based, and proactive.
“By integrating MyOme’s comprehensive genomic testing through Nest’s platform, our clinicians can bring precision medicine into routine visits — helping women understand their health risks sooner and take informed action to prevent disease.”
